iSpecimen Inc. Completes $4 Million Underwritten Offering
WOBURN, Mass. – iSpecimen Inc. (Nasdaq: ISPC), a prominent online global marketplace that connects researchers with healthcare specimen providers, has successfully completed its public offering of 5,714,283 shares of common stock, raising approximately $4 million. This offering took place at a public price of $0.70 per share and marks a significant step for the company in its ongoing mission to advance medical research.
Utilization of Proceeds
The company has outlined its plans for the funds acquired from this offering. Specifically, iSpecimen intends to allocate $1.5 million toward marketing and advertising initiatives led by IR Agency LLC. Additionally, $1 million will support an initial payment to Sales Stack Solutions Corp., which is crucial for their collaborative projects. The remaining funds are earmarked for working capital and other general corporate purposes, allowing the company to structure itself for future growth sustainably.
Details of the Offering
This underwritten offering was performed on a firm commitment basis, with WestPark Capital, Inc. serving as the Sole Book-Runner. This structure illustrates the strong market interest and confidence surrounding iSpecimen’s operations and future prospects. As outlined in the registration statement, approved by the Securities and Exchange Commission, all details regarding the offering are available for review.
About iSpecimen
iSpecimen plays a vital role in the medical research landscape by facilitating an efficient online marketplace for human biospecimens. The platform connects scientists from various sectors, including commercial and non-profit organizations, with healthcare providers possessing essential specimens. With proprietary, cloud-based technology, researchers can easily search for the required specimens and patients. This innovative approach is integral to advancing medical discovery and enhancing the efficiency of research processes.
Future Outlook
As iSpecimen positions itself with new resources from this funding, it aims to deepen its impact in the field of biospecimen research. By enhancing marketing efforts and solidifying partnerships with key organizations, iSpecimen is set to improve its market footprint. The company is committed to delivering valuable solutions for those in need of biospecimens, continuing its mission to support medical research.
Contact Information
For inquiries regarding investor relations, please reach out to KCSA Strategic Communications. Phil Carlson is available for further information at iSpecimen@kcsa.com.
Frequently Asked Questions
What is iSpecimen Inc.?
iSpecimen Inc. is an online marketplace connecting scientists with healthcare providers for obtaining biospecimens needed for medical research.
How much has iSpecimen raised in the recent offering?
iSpecimen has successfully raised approximately $4 million through its recent underwritten public offering.
What will the proceeds from the offering be used for?
The proceeds will be allocated for marketing services, payments to partners, and general corporate purposes to support the company's growth.
Who acted as the Sole Book-Runner for the offering?
WestPark Capital, Inc. served as the Sole Book-Runner during the offering, supporting iSpecimen in this financial endeavor.
Is iSpecimen's registration statement available for public access?
Yes, the registration statement and related information can be accessed through the Securities and Exchange Commission's website.
